Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.

ABSTRACT: Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.

SUBMITTER: Lauder SN 

PROVIDER: S-EPMC8368216 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature